Literature DB >> 10553788

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

G Dornadula1, H Zhang, B VanUitert, J Stern, L Livornese, M J Ingerman, J Witek, R J Kedanis, J Natkin, J DeSimone, R J Pomerantz.   

Abstract

CONTEXT: Despite suppressive treatment with highly active antiretroviral therapy (HAART), replication-competent virus can still be isolated from peripheral blood mononuclear cells and genital cells of many individuals receiving suppressive HAART.
OBJECTIVE: To determine whether free virion RNA can be detected in the blood plasma and/or genital tract fluids from patients receiving suppressive HAART.
DESIGN: Prospective cohort study conducted from November 1998 to May 1999.
SETTING: Academic medical center. PATIENTS: Human immunodeficiency virus 1-infected individuals (20 men and 2 women) shown in our laboratories to have fewer than 50 copies/mL of HIV-1 RNA in peripheral blood plasma while taking suppressive HAART. MAIN OUTCOME MEASURES: Free virion RNA levels in peripheral blood plasma and genital fluids, quantified using an ultrasensitive reverse transcriptase polymerase chain reaction able to quantify cell-free virion RNA to a lower limit of 5 copies/mL and qualitatively detect viral RNA below this level.
RESULTS: In all 22 patients, residual viral RNA could be detected in the peripheral blood plasma (mean level, 17 copies/mL). The presence of viral RNA suggests that ongoing viral replication is occurring, albeit at low levels, in each patient evaluated. Viral RNA levels were lower in most patients' genital fluids compared with blood plasma and in 12 patients were undetectable.
CONCLUSIONS: These data suggest that low-level replication of HIV-1 in patients taking suppressive HAART may be demonstrated not only in peripheral blood mononuclear cells but also in peripheral plasma as cell-free virion RNA. Complete ablation of viral replication may require intensification of antiretroviral therapies beyond standard suppressive HAART.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553788     DOI: 10.1001/jama.282.17.1627

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  172 in total

1.  Benchmarks for antiretroviral therapy.

Authors:  O J Cohen; A S Fauci
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

2.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.

Authors:  D Persaud; T Pierson; C Ruff; D Finzi; K R Chadwick; J B Margolick; A Ruff; N Hutton; S Ray; R F Siliciano
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

3.  Latency and viral persistence in HIV-1 infection.

Authors:  J D Siliciano; R F Siliciano
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

4.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Authors:  M C Strain; H F Günthard; D V Havlir; C C Ignacio; D M Smith; A J Leigh-Brown; T R Macaranas; R Y Lam; O A Daly; M Fischer; M Opravil; H Levine; L Bacheler; C A Spina; D D Richman; J K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

5.  T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity.

Authors:  A Giovannetti; M Pierdominici; F Mazzetta; S Salemi; M Marziali; D Kuonen; F Iebba; E A Lusi; A Cossarizza; F Aiuti
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 6.  Latency in human immunodeficiency virus type 1 infection: no easy answers.

Authors:  Deborah Persaud; Yan Zhou; Janet M Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 7.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 8.  HIV latency.

Authors:  Robert F Siliciano; Warner C Greene
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 9.  Measuring the latent reservoir in vivo.

Authors:  Marta Massanella; Douglas D Richman
Journal:  J Clin Invest       Date:  2016-02-01       Impact factor: 14.808

10.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.